FOR A FREE CASE EVALUATION, CALL 1-800-632-1404

If you took Actos® (pioglitazone) for a year or longer and have been diagnosed with bladder cancer, call the Actos bladder cancer lawyers with our firm at 1-800-632-1404. Our firm is currently reviewing cases involving persons who took Actos® for control of blood sugar.

BACKGROUND

One of the alleged side effects of Actos is bladder cancer. The treatment of bladder cancer is based on the stage and overall condition of the patient. Recently, a court in Los Angeles, California consolidated several proceedings there, which now confirms there are two main sources of litigation for Actos: state court in California and a MDL federal proceeding in the Western District of Louisiana.

During the hearing held in Los Angeles, defendant Takeda stated to the court that it will move to transfer all pending California filed cases to the newly formed federal MDL (multi-district litigation) in the Western District of Louisiana. Plaintiff’s counsel countered this statement, arguing that the current California cases have a legitimate basis for filing in California jurisdiction due to the operations of their Takeda San Diego facility and will seek to oppose Takeda’s efforts to remove California Actos plaintiffs to Federal Court.

Actos (pioglitazone), approved by the FDA to treat type 2 diabetes mellitus, has been at the center of controversy since reports surfaced in June of 2011 linking the drug with a significant risk of bladder cancer. Studies showed that the risk of bladder cancer increased considerably with Actos exposure of longer than one year. The European Medicine Agency and the Federal Institute for Drugs and Medical Devices subsequently suspended the use Actos.

The U.S. Food and Drug Administration (FDA) issued a public announcement on June 15, 2011, alerting the public of the increased risk of bladder cancer associated with Actos. According to the FDA, a 40 percent increased risk for bladder cancer was seen in patients taking Actos for over a year when compared to people not taking the drug.

The agency stated that information about this risk would be added to the labeling of any pioglitazone-containing medication. The FDA further recommended that diabetes patients diagnosed with bladder cancer stop the use of Actos or pioglitazone.

Actos patients should seek legal representation and maximum compensation if they have been diagnosed with bladder cancer or are experiencing urinary bleeding.

BACKGROUND

Since 1999, Actos® has been prescribed as part of an overall treatment regimen for controlling blood sugar in diabetic patients. In recent years it has also been prescribed as a diabetes preventative in those who show the early signs of the disease. In September 2010, the U.S. Food and Drug Administration (FDA) began a safety review of Actos® when new data was discovered that suggested a link to increased risk of bladder cancer.

The risk of bladder cancer is MUCH HIGHER for those that take the drug at higher cumulative doses and for longer periods of time. This increased risk is also greater in men than in women. The FDA has issued a warning of the elevated risk to patients who have been taking Actos®, but added that patients should not stop taking Actos® unless instructed to do so by their physicians. The active ingredient in Actos® is also contained in other drugs, namely Actoplus Met®, Actoplus Met XR®, and Duetact®.

Although Actos® continues to remain on the shelves of drug stores in the United States, the drug is under a long-term observational study by the FDA. France suspended the drug and Germany recommended not to start new patients on the drug due to mounting concerns for their citizens.

RISK OF BLADDER CANCER

In June of this year the U.S. Food & Drug Administration (FDA) issued a warning about the popular diabetes drug Actos(pioglitazone). The FDA had found that the use of pioglitazone for more than a year may be linked to an increased risk of bladder cancer.

SYMPTOMS OF BLADDER CANCER

Common symptoms of Actos®-related bladder cancer may include:

• ■Blood in urine, sometimes creating a change in urine color
• ■Frequent urination
• ■Painful urination
• ■Urinary tract infection

If you or a loved one developed bladder cancer during or after taking Actos®, Actoplus Met®, Actoplus Met XR®, or Duetact®, call us now at 1-800-632-1404 or SUBMIT A SHORT CASE FORM HERE for a free, no obligation, evaluation of your case.

HERE TO HELP.

If you are interested in claims for Actos, an Actos lawsuit, information on an Actos class action, or want to speak with anActos attorney, please call us today at 1-800-632-1404.

Members of our firm are attorneys currently representing clients who have taken several prescription drugs and claim injuries associated with those drugs, including Topamax®, Wellbutrin®, Fosamax®, and Actos®. Members of the firm also represent clients across the globe pertaining to medical device failures, including the Advanced Bionics HiRes90k® cochlear implant , the TVM / TVT transvaginal mesh – sling and the DePuy hip implant. For a free case evaluation, please contact:

CALL US TOLL FREE: (800) 632-1404

EMAIL: click here

FILL OUT THIS FORM:

NOTE: Our team of attorneys will review potential cases for all fifty states, including Alabama Alaska Arizona Arkansas California Colorado Connecticut Delaware Florida Georgia Hawaii Idaho Illinois Indiana Iowa Kansas Kentucky Louisiana Maine Maryland Massachusetts Michigan Minnesota Mississippi Missouri Montana Nebraska Nevada New Hampshire New Jersey New Mexico New York North Carolina North Dakota Ohio Oklahoma Oregon Pennsylvania Rhode Island South Carolina South Dakota Tennessee Texas Utah Vermont Virginia Washington West Virginia Wisconsin and Wyoming.